Inmune Bio (INMB) Equity Ratio (2017 - 2025)
Historic Equity Ratio for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to 0.76.
- Inmune Bio's Equity Ratio rose 382.76% to 0.76 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.76, marking a year-over-year increase of 382.76%. This contributed to the annual value of 0.81 for FY2024, which is 2384.95% up from last year.
- Per Inmune Bio's latest filing, its Equity Ratio stood at 0.76 for Q3 2025, which was up 382.76% from 0.77 recorded in Q2 2025.
- Inmune Bio's Equity Ratio's 5-year high stood at 0.96 during Q1 2021, with a 5-year trough of 0.6 in Q1 2024.
- Moreover, its 5-year median value for Equity Ratio was 0.76 (2022), whereas its average is 0.76.
- As far as peak fluctuations go, Inmune Bio's Equity Ratio crashed by 2429.72% in 2021, and later skyrocketed by 3025.42% in 2025.
- Quarter analysis of 5 years shows Inmune Bio's Equity Ratio stood at 0.8 in 2021, then decreased by 8.46% to 0.73 in 2022, then fell by 10.85% to 0.66 in 2023, then grew by 23.85% to 0.81 in 2024, then dropped by 6.23% to 0.76 in 2025.
- Its Equity Ratio was 0.76 in Q3 2025, compared to 0.77 in Q2 2025 and 0.78 in Q1 2025.